Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
3
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
0 competitors in Primary Osteoporosis
View Full LandscapeNo patent data available. Pre-approval drugs may not have Orange Book listings.
Bondenza (previously Ibandronic Acid Roche)
Treatment of osteoporosis in post-menopausal women at increased risk of fracture. A reduction in the risk of vertebral fractures has been demonstrated. Efficacy on femoral-neck fractures has not been established.
View on EMABondronat
Bondronat is indicated for: prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases; treatment of tumour-induced hypercalcaemia with or without metastases.
View on EMADestara
Treatment of tumour-induced hypercalcaemia with or without metastases.
View on EMA